Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 12 sources · 3 days · First seen 6 days ago · Last updated 4 days ago

Xeris Biopharma financial performance and analyst updates

Overview

Xeris Biopharma reported significant growth in its Recorlev revenue, which rose 81% year-over-year to approximately $56.8 million in the second quarter of 2026. The company also received a U.S. patent notice for Keveyis, extending its intellectual property protection through 2039.

Following this, the company reported quarterly revenue of $92.10 million, exceeding expectations, though its earnings per share (EPS) of ($0.18) missed consensus estimates. In response to these financial results, HC Wainwright lowered its Q3 2026 EPS forecast from $0.02 to $0.01. Other analysts have also adjusted their ratings for the stock, moving from ‘strong-buy’ to ‘buy’ or from ‘sell’ to ‘hold.’

Entities

Keveyis · Trane Technologies plc · JBT Marel Corporation · HC Wainwright · Applied Materials, Inc.

Timeline

4 days ago

[BUSINESS] 11 sources
Global corporations report varied financial results amid AI and tech shifts
Major companies including Bloom Energy, JPMorgan Chase, and Apple report diverse financial outcomes driven by AI infrastructure demand, semiconductor trends, and shifting market valuations.
6 days ago

[BUSINESS] 2 sources
Xeris Biopharma reports revenue surge as Trane Technologies sees institutional shifts
Xeris Biopharma reported an 81% surge in Recorlev revenue and secured a new patent for Keveyis, while institutional investors adjusted their positions in Trane Technologies plc.

Sources

europesays.com · finanzen.at · finanzen.net · finnewsnetwork.com.au · fool.com.au · ibtimes.com.au · lesgrandsmaitres.fr · mommygearest.com · pulse2.com · seekingalpha.com · stocknews.com · tradingview.com

This summary has been updated 1 time: see revision history